255 related articles for article (PubMed ID: 22151412)
21. Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts.
Ortiz M; Córdoba J; Alonso J; Rovira A; Quiroga S; Jacas C; Esteban R; Guardia J
J Hepatol; 2004 Mar; 40(3):552-7. PubMed ID: 15123374
[TBL] [Abstract][Full Text] [Related]
22. Effect of blood ammonia elevation following oral glutamine load on the psychometric performance of cirrhotic patients.
Masini A; Efrati C; Merli M; Nicolao F; Amodio P; Del Piccolo F; Riggio O
Metab Brain Dis; 2003 Mar; 18(1):27-35. PubMed ID: 12603080
[TBL] [Abstract][Full Text] [Related]
23. Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy.
Douglass A; Al Mardini H; Record C
J Hepatol; 2001 May; 34(5):658-64. PubMed ID: 11434611
[TBL] [Abstract][Full Text] [Related]
24. Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy.
Ampuero J; Gil A; Viloria MDM; Rico MC; Millán R; Camacho I; Romero-Gómez M
Liver Int; 2020 Apr; 40(4):921-930. PubMed ID: 31729816
[TBL] [Abstract][Full Text] [Related]
25. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P; Sharma BC; Sarin SK
Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
[TBL] [Abstract][Full Text] [Related]
26. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis.
Montoliu C; Cauli O; Urios A; ElMlili N; Serra MA; Giner-Duran R; González-Lopez O; Del Olmo JA; Wassel A; Rodrigo JM; Felipo V
Am J Gastroenterol; 2011 Sep; 106(9):1629-37. PubMed ID: 21483460
[TBL] [Abstract][Full Text] [Related]
27. [Minimal hepatic encephalopathy detection by neuropsychological and neurophysiological methods and the role of ammonia for its diagnosis].
Bragagnolo MA; Teodoro V; Lucchesi LM; Ribeiro TC; Tufik S; Kondo M
Arq Gastroenterol; 2009; 46(1):43-9. PubMed ID: 19466309
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
29. Predictors of minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P; Sharma BC
Saudi J Gastroenterol; 2010; 16(3):181-7. PubMed ID: 20616413
[TBL] [Abstract][Full Text] [Related]
30. Effect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an effect of nonabsorbable disaccharides on small intestine ammonia generation.
Masini A; Efrati C; Merli M; Attili AF; Amodio P; Ceccanti M; Riggio O
Am J Gastroenterol; 1999 Nov; 94(11):3323-7. PubMed ID: 10566738
[TBL] [Abstract][Full Text] [Related]
31. Bispectral index monitoring for diagnosis and assessment of severity of hepatic encephalopathy in cirrhotic patients.
Jindal A; Sharma BC; Sachdeva S; Chawla R; Srivastava S; Maharshi S
Dig Liver Dis; 2015 Sep; 47(9):769-74. PubMed ID: 26022229
[TBL] [Abstract][Full Text] [Related]
32. Ammonia levels and the severity of hepatic encephalopathy.
Qureshi MO; Khokhar N; Shafqat F
J Coll Physicians Surg Pak; 2014 Mar; 24(3):160-3. PubMed ID: 24613109
[TBL] [Abstract][Full Text] [Related]
33. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
[TBL] [Abstract][Full Text] [Related]
34. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS.
Gioia S; Merli M; Nardelli S; Lattanzi B; Pitocchi F; Ridola L; Riggio O
Liver Int; 2019 May; 39(5):871-877. PubMed ID: 30667572
[TBL] [Abstract][Full Text] [Related]
35. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Weiss N; Tripon S; Lodey M; Guiller E; Junot H; Monneret D; Mayaux J; Brisson H; Mallet M; Rudler M; Imbert-Bismut F; Thabut D;
Fundam Clin Pharmacol; 2018 Apr; 32(2):209-215. PubMed ID: 29239015
[TBL] [Abstract][Full Text] [Related]
36. Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE).
Formentin C; Zarantonello L; Mangini C; Frigo AC; Montagnese S; Merkel C
Liver Int; 2021 May; 41(5):1070-1082. PubMed ID: 33411388
[TBL] [Abstract][Full Text] [Related]
37. Altered postural control and stability in cirrhotic patients with minimal hepatic encephalopathy correlate with cognitive deficits.
Urios A; Mangas-Losada A; Gimenez-Garzó C; González-López O; Giner-Durán R; Serra MA; Noe E; Felipo V; Montoliu C
Liver Int; 2017 Jul; 37(7):1013-1022. PubMed ID: 27988985
[TBL] [Abstract][Full Text] [Related]
38. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
Sharma P; Sharma BC; Agrawal A; Sarin SK
J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
[TBL] [Abstract][Full Text] [Related]
39. Neuropsychological impairment in severe acute viral hepatitis is due to minimal hepatic encephalopathy.
Sharma P; Sharma BC; Tyagi P; Kumar M; Sarin SK
Liver Int; 2009 Feb; 29(2):260-4. PubMed ID: 18710429
[TBL] [Abstract][Full Text] [Related]
40. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
